Shrinking lung syndrome in pregnancy complicated by antiphospholipid antibody syndrome.
BACKGROUND
Shrinking lung syndrome is characterized by pulmonary compromise secondary to unilateral or bilateral paralysis of the diaphragm.


METHODS
Shrinking lung syndrome was diagnosed in a patient with antiphospholipid syndrome after a cesarean delivery at 28 4/7 weeks of gestation. Signs and symptoms included unexplained right-side chest pain, dyspnea, tachypnea, and absent breath sounds at the right base of the lungs. After initiation of corticosteroids, her symptoms resolved.


CONCLUSIONS
Although seen in association with systemic lupus erythematosus, shrinking lung syndrome has not been described with antiphospholipid syndrome or during pregnancy. Diagnosis and awareness are important because treatment with moderate- to high-dose corticosteroids appears to improve the clinical outcome.
From the Division of Maternal Fetal Medicine and the Mayo Medical School, Mayo Clinic College of Medicine, Rochester, Minnesota.
Monika
M
Meena
Christopher C
CC
DeStephano
William J
WJ
Watson
Brian C
BC
Brost
D000328:Adult; D016736:Antiphospholipid Syndrome / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D002585:Cesarean Section; D002637:Chest Pain / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy; D004417:Dyspnea / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006985:Hyperventilation / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy; D008171:Lung Diseases / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy; D010100:Oxygen / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis* / Q000188:drug therapy; D011859:Radiography; D012133:Respiratory Paralysis / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy; D012135:Respiratory Sounds / Q000175:diagnosis / Q000187:drug effects; D013577:Syndrome; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use
D014859:Warfarin; D006493:Heparin; D011239:Prednisolone; D001241:Aspirin; D010100:Oxygen
Hoffbrand BI, Beck ER. “Unexplained” dyspnoea and shrinking lungs in systemic lupus erythematosus. BMJ 1965;1:1273–7.
Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res 2009;23:469–80.
Warrington KJ, Moder KG, Brutinel WM. The shrinking lungs syndrome in systemic lupus erythematosus. Mayo Clin Proc 2000;75:467–72.
Bertoli AM, Vila LM, Apte M, Fessler BJ, Bastian HM, Reveille JD, et al. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus 2007;16:410–7.
Carmier D, Marchand-Adam S, Diot P, Diot E. [Respiratory involvement in systemic lupus erythematosus]. Rev Mal Respir 2008;25:1289–303.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
Toya SP, Tzelepis GE. Association of the shrinking lung syndrome in systemic lupus erythematosus with pleurisy: a systematic review. Semin Arthritis Rheum 2009;39:30–7.
Oud KT, Bresser P, ten Berge RJ, Jonkers RE. The shrinking lung syndrome in systemic lupus erythematosus: improvement with corticosteroid therapy. Lupus 2005;14:959–63.
Mallick S, Petkova D. Investigating suspected pulmonary embolism during pregnancy. Respir Med 2006;100: 1682–7.
Stojanovich L. Pulmonary manifestations in antiphospholipid syndrome. Autoimmunity reviews 2006;5:344–8.
Raj R, Murin S, Matthay RA, Wiedemann HP. Systemic lupus erythematosus in the intensive care unit. Crit Care Clin 2002;18:781–803.